These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2447806)

  • 21. Phenotypic and functional characterization of vaginal dendritic cells in a rat model of Candida albicans vaginitis.
    De Bernardis F; Lucciarini R; Boccanera M; Amantini C; Arancia S; Morrone S; Mosca M; Cassone A; Santoni G
    Infect Immun; 2006 Jul; 74(7):4282-94. PubMed ID: 16790803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of anti-Candida albicans IgE antibodies in vaginal washes from patients with acute vulvovaginal candidiasis.
    Regúlez P; García Fernández JF; Moragues MD; Schneider J; Quindós G; Pontón J
    Gynecol Obstet Invest; 1994; 37(2):110-4. PubMed ID: 8150365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The protective immune response against vaginal candidiasis: lessons learned from clinical studies and animal models.
    Fidel PL
    Int Rev Immunol; 2002; 21(6):515-48. PubMed ID: 12650240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological investigations in vaginal mycoses.
    Mendling W; Koldovsky U
    Mycoses; 1996; 39(5-6):177-83. PubMed ID: 8909027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Recurrent vaginitis].
    Maruotti T; Reverberi L; Figliolini M; Pacchiarotti U; Alessandro A; Di Rosa R
    Ann Ig; 1989; 1(6):1465-78. PubMed ID: 2484480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [IgA, IgE and IgG subclasses to Candida albicans in serum and vaginal fluid from patients with vulvovaginal candidiasis].
    de Carvalho RJ; Cunha CM; Silva DA; Sopelete MC; Urzedo JE; Moreira TA; Moraes Pde S; Taketomi EA
    Rev Assoc Med Bras (1992); 2003; 49(4):434-8. PubMed ID: 14963598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrent vaginal candidiasis. Importance of an intestinal reservoir.
    Miles MR; Olsen L; Rogers A
    JAMA; 1977 Oct; 238(17):1836-7. PubMed ID: 333134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Candida albicans allergen immunotherapy in recurrent vaginal candidiasis.
    Moraes PS; de Lima Goiaba S; Taketomi EA
    J Investig Allergol Clin Immunol; 2000; 10(5):305-9. PubMed ID: 11108444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of vaginal Candida infections.
    Sobel JD
    Expert Opin Pharmacother; 2002 Aug; 3(8):1059-65. PubMed ID: 12150685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Candida vaginitis: virulence, host response and vaccine prospects.
    De Bernardis F; Graziani S; Tirelli F; Antonopoulou S
    Med Mycol; 2018 Apr; 56(suppl_1):26-31. PubMed ID: 29538739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recurrent allergic vulvovaginitis: treatment with Candida albicans allergen immunotherapy.
    Rigg D; Miller MM; Metzger WJ
    Am J Obstet Gynecol; 1990 Feb; 162(2):332-6. PubMed ID: 2178425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of rDNA restriction fragment length polymorphisms to differentiate strains of Candida albicans in women with vulvovaginal candidiasis.
    Stein GE; Sheridan VL; Magee BB; Magee PT
    Diagn Microbiol Infect Dis; 1991; 14(6):459-64. PubMed ID: 1686996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local immune responsiveness following intravaginal challenge with Candida antigen in adult women at different stages of the menstrual cycle.
    Fidel PL; Barousse M; Lounev V; Espinosa T; Chesson RR; Dunlap K
    Med Mycol; 2003 Apr; 41(2):97-109. PubMed ID: 12964841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhalant allergy compounding the chronic vaginitis syndrome: characterization of sensitization patterns, comorbidities and responses to sublingual immunotherapy.
    Theodoropoulos DS; Stockdale CK; Duquette DR; Morris MS
    Arch Gynecol Obstet; 2016 Sep; 294(3):541-8. PubMed ID: 27040422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased severity of Candida vaginitis in BALB/c nu/nu mice versus the parent strain is not abrogated by adoptive transfer of T cell enriched lymphocytes.
    Black CA; Eyers FM; Russell A; Dunkley ML; Clancy RL; Beagley KW
    J Reprod Immunol; 1999 Nov; 45(1):1-18. PubMed ID: 10660259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole.
    Sobel JD; Kapernick PS; Zervos M; Reed BD; Hooton T; Soper D; Nyirjesy P; Heine MW; Willems J; Panzer H; Wittes H
    Am J Obstet Gynecol; 2001 Aug; 185(2):363-9. PubMed ID: 11518893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenesis and treatment of recurrent vulvovaginal candidiasis.
    Sobel JD
    Clin Infect Dis; 1992 Mar; 14 Suppl 1():S148-53. PubMed ID: 1562688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
    Mendling W; Brasch J; Cornely OA; Effendy I; Friese K; Ginter-Hanselmayer G; Hof H; Mayser P; Mylonas I; Ruhnke M; Schaller M; Weissenbacher ER
    Mycoses; 2015 Mar; 58 Suppl 1():1-15. PubMed ID: 25711406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunologic factors influencing susceptibility to recurrent candidal vaginitis.
    Witkin SS
    Clin Obstet Gynecol; 1991 Sep; 34(3):662-8. PubMed ID: 1934716
    [No Abstract]   [Full Text] [Related]  

  • 40. Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis.
    Raska M; Belakova J; Horynova M; Krupka M; Novotny J; Sebestova M; Weigl E
    Med Mycol; 2008 Aug; 46(5):411-20. PubMed ID: 18608941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.